Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 313

The DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.

Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors

Open access
Le Romancer, Muriel, Poulard, Coralie, Cohen, Pascale, Sentis, Stéphanie, Renoir, Jack-Michel, Corbo, Laura·2011·Endocrine Reviews

Abstract

Estrogen signaling pathways, because of their central role in regulating the growth and survival of breast tumor cells, have been identified as suitable and efficient targets for cancer therapies.Agents blocking estrogen activity are already widely used clinically, and many new molecules have entered clinical trials, but intrinsic or acquired resistance to treatment limits their efficacy.The basic molecular studies underlying estrogen signaling have defined the critical role of estrogen receptors (ER) in many aspects of breast tumorigenesis.However, important knowledge gaps remain about the role of posttranslational modifications (PTM) of ER in initiation and progression of breast carcinogenesis.Whereas major attention has been focused on the phosphorylation of ER, many other PTM (such as acetylation, ubiquitination, sumoylation, methylation, and palmitoylation) have been identified as events modifying ER expression and stability, subcellular localization, and sensitivity to hormonal response.This article will provide an overview of the current and emerging knowledge on ER PTM, with a particular focus on their deregulation in breast cancer.We also discuss their clinical relevance and the functional relationship between PTM.A thorough understanding of the complete picture of these modifications in ER carcinogenesis might not only open new avenues for identifying new markers for prognosis or prediction of response to endocrine therapy but also could promote the development of novel therapeutic strategies.(Endocrine Reviews 32: 597-622, 2011) I. Introduction II.Biology of Estrogen Receptors and Breast Cancer A. ER␣ and ER␤ subtypes B. Genomic action of ER C. Nongenomic action of ER D. Endocrine therapies in breast cancer III.Posttranslational Modifications of Estrogen Receptors A. PTM involved in ER genomic signaling B. PTM involved in ER nongenomic signaling C. Molecular events affecting ER PTM D. ER PTM deregulated in breast cancer IV. Discussion V.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2010-0016

Cites

255 of 255 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 255 references

Cited by

See all 313

Metadata

Authors
Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J.-M., & Corbo, L.
Venue
Endocrine Reviews
Published
2011-06-15
Volume
32
Issue
5
Pages
597-622
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2121971175
Cited by
313
References
255
FWCI
13.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors. https://app.cochat.ai/papers/10.1210/er.2010-0016
The paper
Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J.-M., & Corbo, L. (2011). Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors. Endocrine Reviews. https://doi.org/10.1210/er.2010-0016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.